In-silico Targets in Neurodegenerative Disorders
Parkinson’s disease (PD), Alzheimer’s disease (AD) are very frequent human neurodegenerative diseases. Their pharmacological treatment has not been solved; therefore, there is a need to investigate and discover new drug candidates and new targets. Modification of endogenous chemicals can offer new candidates with improved therapeutic outcomes. Computational chemistry can support the discovery of such candidates and can further improve the execution speed, decrease cost and the usage of test animals. These methods for example can include cheminformatics, docking and molecular dynamics. Computational biology offers a way for discovery of novel pharmacological targets and can pinpoint the genetic background of such diseases. In this chapter, we would like to discuss the possible targets of the two most common neurological diseases, AD and PD. The known and the possible new targets are shown and their therapeutic importance is also detailed. In addition, the methods of their discovery is highlighted demonstrating the importance of the in silico discovery of new targets in neurological diseases.
KeywordsAlzheimer’s disease Parkinson’s disease In silico targets Drug development Computational sciences
- Alzheimer’s association. FDA approved treatments for Alzheimer’s 800.272.3900 alz.org ®. 2017.
- Cell Signaling Technology, Inc. (www.cellsignal.com).Google Scholar
- Dias Viegas FP, de Freitas Silva M, Divino da Rocha M, Castelli MR, Riquiel MM, Machado RP, et al. Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazonederivatives as donepezil hybrids: discovery of novel multi-target anti-alzheimer prototype drug candidates. Eur J Med Chem. 2018;147:48–65.CrossRefGoogle Scholar
- Fernández-Suárez D, Celorrio M, Riezu-Boj JI, Ugarte A, Pacheco R, González H, Oyarzabal J, Hillard CJ, Franco R, Aymerich MS. The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiol Aging. 2014;35:2603–16.CrossRefGoogle Scholar
- Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 Investigators. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, doubleblind, controlled trial. Lancet Neurol. 2016;15:154–65.CrossRefGoogle Scholar
- Gao L, Fang JS, Bai XY, Zhou D, Wang YT, Liu AL, Du GH. In silico target fishing for the potential targets and molecular mechanisms of baicalein as an antiparkinsonian agent: discovery of the protective effects on NMDA receptor-mediated neurotoxicity. Chem Biol Drug Des. 2013;81:675–87.CrossRefGoogle Scholar
- Houghton D, Hurtig H, Metz S, Giroux M, Petzinger G, Fisher B, Hawthorne L, Jakowec M. Parkinson’s disease medications. National Parkinson Foundation. 2018. www.parkinson.org.
- Jalili-Baleh L, Forootanfar H, Küçükkılınç TT, Nadri H, Abdolahi Z, Ameri A, Jafari M, Ayazgok B, Baeeri M, Rahimifard M, Abbas Bukhari SN, Abdollahi M, Ganjali MR, Emami S, Khoobi M, Foroumadi A. Design, synthesis and evaluation of novel multi-target-directed ligands for treatment of Alzheimer’s disease based on coumarin and lipoic acid scaffolds. Eur J Med Chem. 2018;152:600–14.CrossRefGoogle Scholar
- PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196–205.CrossRefGoogle Scholar
- Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26:S42–80.CrossRefGoogle Scholar
- Silva GS, Figueiró M, Tormena CF, Coelho F, Almeida WP. Effects of novel acylhydrazones derived from 4-quinolone on the acetylcholinesterase activity and Aβ 42 peptide fibrils formation. J Enzyme Inhib Med Chem. 2016;6366:1–7.Google Scholar